Format

Send to

Choose Destination
Proc Nutr Soc. 2018 May;77(2):135-151. doi: 10.1017/S0029665118000046.

A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes.

Author information

1
School of Food and Nutritional Sciences,College of Science, Engineering and Food Science,University College Cork,Ireland.
2
Department of Agricultural, Food and Nutritional Science,University of Alberta,Edmonton, Alberta,Canada.

Abstract

Advancements in image-based technologies and body composition research over the past decade has led to increased understanding of the importance of muscle abnormalities, such as low muscle mass (sarcopenia), and more recently low muscle attenuation (MA), as important prognostic indicators of unfavourable outcomes in patients with cancer. Muscle abnormalities can be highly prevalent in patients with cancer (ranging between 10 and 90 %), depending on the cohort under investigation and diagnostic criteria used. Importantly, both low muscle mass and low MA have been associated with poorer tolerance to chemotherapy, increased risk of post-operative infectious and non-infectious complications, increased length of hospital stay and poorer survival in patients with cancer. Studies have shown that systemic antineoplastic treatment can exacerbate losses in muscle mass and MA, with reported loss of skeletal muscle between 3 and 5 % per 100 d, which are increased exponentially with progressive disease and proximity to death. At present, no effective medical intervention to improve muscle mass and MA exists. Most research to date has focused on treating muscle depletion as part of the cachexia syndrome using nutritional, exercise and pharmacological interventions; however, these single-agent therapies have not provided promising results. Rehabilitation care to modify body composition, either increasing muscle mass and/or MA should be conducted, and its respective impact on oncology outcomes explored. Although the optimal timing and treatment strategy for preventing or delaying the development of muscle abnormalities are yet to be determined, multimodal interventions initiated early in the disease trajectory appear to hold the most promise.

KEYWORDS:

CT computed tomography; DLT dose-limiting toxicity; GI gastrointestinal; HR hazard ratio; HU Hounsfield unit; MA muscle attenuation; SMA skeletal muscle area; SMI skeletal muscle index; Body composition; Cachexia; Cancer; Muscle attenuation; Sarcopenia; Survival

PMID:
29745361
DOI:
10.1017/S0029665118000046

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center